Researchers identify the cancer drug LY2090314 as a potent inhibitor of Toxoplasma gondii and Cryptosporidium and report the first crystal structure of the parasite kinase TgGSK3 bound to it, validating TgGSK3 as a therapeutic target.
- Silvia Diaz-Martin
- Christopher Swale
- Alexandre Bougdour
